New study tests if GPS and MRI can keep men off the operating table

NCT ID NCT05424783

Recruiting now Knowledge-focused Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving men with low-risk prostate cancer two extra tests—a genomic test (GPS) and a special MRI—helps them stick with active surveillance (monitoring instead of immediate treatment). Researchers will track 222 men for 18 months to see if these tests improve safety and reduce unnecessary biopsies. The goal is to find the right balance between catching dangerous cancers and avoiding overtreatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Genomic Prostate Score assay and multi-parametric MRI
What this could lead to: If successful, this could show that adding these tests helps men safely avoid or delay aggressive treatment, improving quality of life.
What could go wrong: This is an observational study, not a treatment trial. The tests may cause false alarms leading to unnecessary procedures, and results may not apply to all groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAVORABLE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Northwestern University
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60611, United States
University of Illinois at Chicago
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.